6.2 C
New York
Saturday, November 15, 2025

FDA approves vepdegestrant NDA for ESR1-mutated breast cancer


FDA accepts vepdegestrant NDA for ESR1-mutated breast cancer

Related Articles

Stay Connected

0FansLike
0FollowersFollow
0SubscribersSubscribe

Latest Articles